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Objective: ischaemic lower-extremity ulcers in the diabetic population are a source of major concern because of the
associated high risk of limb-threatening complications. The aim of this study was to evaluate the role of hyperbaric oxygen
in the management of these ulcers.
Method: eighteen diabetic patients with ischaemic, non-healing lower-extremity ulcers were recruited in a double-blind
study. Patients were randomly assigned either to receive 100% oxygen (treatment group) or air (control group), at 2.4
atmospheres of absolute pressure for 90 min daily (total of 30 treatments).
Results: healing with complete epithelialisation was achieved in five out of eight ulcers in the treatment group compared to
one out of eight ulcers in the control group. The median decrease of the wound areas in the treatment group was 100% and
in the control group was 52% (p 0.027). Cost-effectiveness analysis has shown that despite the extra cost involved in
using hyperbaric oxygen, there was a potential saving in the total cost of treatment for each patient during the study.
Conclusion: hyperbaric oxygen enhanced the healing of ischaemic, non-healing diabetic leg ulcers and may be used as a
valuable adjunct to conventional therapy when reconstructive surgery is not possible.
Key Words: Hyperbaric oxygenation; Peripheral arterial diseases; Wound healing; Diabetes mellitus; Randomised
controlled trial.
Introduction
At anytime about 5±7% of the diabetic population are
estimated to have a lower-extremity ulcer of varying
severity.1,2 These ulcers are a source of major concern
because of the high risk of developing serious limb
threatening complications.3,4 Several well-accepted
risk factors predispose diabetic patients to ulceration.
The most important include peripheral arterial disease
(PAD) and peripheral neuropathy.5,6 PAD is a major
contributing factor in 60% of the lower-extremity
ulcers in diabetic patients.1,7 In these ulcers, bacterial
infection is common and wound hypoxia is well
documented.8±10
Hyperbaric oxygen therapy has been demonstrated
to have an antimicrobial effect and to increase oxygen-
ation of the hypoxic wound tissues. This enhances the
neutrophil killing ability, stimulates angiogenesis, and
enhancesfibroblastsactivityandcollagensynthesis.11±14
Despite the seriousness of complications arising
from lower-extremity diabetic ulcers, the international
medical community has not accepted hyperbaric oxy-
gen therapy as an adjunctive treatment because of the
poor quality of reports supporting its use and the
relatively high cost of the treatment.15,16 In view of
this we conducted a double-blinded, randomised-
controlled study to examine the role of hyperbaric
oxygen therapy in the treatment of diabetic lower-
extremity ulcers in patients with PAD. The study
objective was to determine whether hyperbaric oxy-
gen, as compared to control, could have any thera-
peutic effect on these ulcers. Secondary objectives
included the influence of hyperbaric oxygen on qual-
ity of life measures and a limited economic evaluation
of its use.
Patients and Methods
Participants
Diabetic patients presenting to Hull Royal Infirmary
with ischaemic lower-extremity ulcers were recruited
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if they had an ulcer more than 1 cm and less than
10 cm in maximum diameter which had not shown
any signs of healing, despite optimum medical man-
agement for more than 6 weeks since presenting.
Occlusive arterial disease was confirmed by an ankle-
brachial pressure index 50.8 (or great toe-brachial
pressure index 50.7 if calf vessels were incompress-
ible). Acceptable metabolic control of their diabetes
was judged by glycated haemoglobin level of less
than 8.5%. All patients underwent diagnostic angiog-
raphy as part of their vascular assessment. Decision
on vascular intervention was made by the clinician
responsible for the care of each patient. In general,
the four consultant vascular surgeons in Hull are rela-
tively aggressive in relation to distal revascularisation.
Patients for whom vascular surgery, angioplasty or
thrombolysis was planned were excluded. The study
was approved by the local ethics committee and
informed consent was obtained from all patients. The
trial started in April 1999 and ended in April 2001.
Intervention and randomisation
Patients were randomly assigned either to receive
hyperbaric 100% oxygen (treatment group) or hyper-
baric air (control group). The randomisation was per-
formed using sealed envelopes and the randomisation
code was only known to the chamber operator. All
patients, their carers and medical assessors were
blinded to the treatment. The treatment in both groups
was given in a multi-place chamber via hood at a
pressure of 2.4 atmospheres absolute (ATA) for
90 min daily, 5 days per week, totalling 30 sessions.
Decompression time was extended to 20 min to avoid
giving oxygen supplement during decompression to
the control group without compromising their safety.
Medical management was optimised and equivalent
for all patients in both groups. All patients regularly
attended a specialised multi-disciplinary clinic com-
prising a diabetic physician, a vascular surgeon, a
chiropodist and a specialist nurse, for at least 6 weeks
before recruitment into this study and throughout the
study treatment and follow up period. Wound care
was standardised for all patients and included off-
loading, aggressive debridement and dressing which
ensured that a moist wound environment was main-
tained. Antibiotic therapy was given if there were
clinical signs of infection.
Evaluation of response to treatment
Any patient with more than one ulcer had only one of
the ulcers selected at random to be included in the
study. The primary outcome was the ulcer surface
area measurement. Ulcers were copied into a trans-
parent sheet and then transferred into a digital image.
Surface area was calculated using a special software
program (SigmaScan1). Complete healing was docu-
mented if complete epithelialisation of the ulcer was
evident. Ulcer assessment also included measuring
ulcer depth and looking for clinical signs of infection.
Quality of life was measured using the generic form
SF-36 and Hospital Anxiety and Depression Scale
(HAD scale).
Patients were assessed at baseline, after 15 and after
30 treatments, and 6 weeks later. Two more follow-
up visits were performed at 6 months and 1 year.
The primary objective of this study was to deter-
mine whether there was a significant reduction in
the ulcer size at six weeks after the end of the
intervention.
Cost effectiveness analysis
The mean total cost of visits for ulcer dressing per
patient during the 1 year follow-up period of the
study in the control group was compared with the
respective cost in the treatment group in addition to
the cost of hyperbaric oxygen treatment per patient
and the cost of dealing with any complications arising
from the treatment. The estimated costs of an out-
patient hospital visit for ulcer dressing is £58 (figure
obtained from NHS Executive 2000 costs for the U.K.).
The standard amount charged by the Hull Hyperbaric
Unit for hyperbaric oxygen therapy per patient is £100
for each session.
Statistical analysis
Sample size was based on similar work on venous
ulcers.17 Data analysis was on an intention-to-treat
basis. A p-value of less than 0.05 was considered to
be significant. When distribution did not satisfy the
parametric assumptions, non-parametric tests were
used. The analyses were performed using SPSS
version 9.0.
Results
Of 25 patients screened, five were excluded because
they did not conform to inclusion criteria and two
patients refused to take part in the study. None of
the patients were suitable for straightforward vascu-
lar reconstructive surgery. Eighteen patients were
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randomised into one of two groups (nine treatment
and nine control). Two patients withdrew during
the course of the study (one in the control group
required urgent vascular intervention and one in the
treatment group dropped out for personal reasons).
The protocol was strictly followed throughout the
study. All patients received their treatment as out-
patients and no adverse events related to hyperbaric
therapy were recorded during the study period.
Patients' characteristics are shown in Table 1.
At 6 weeks follow up, complete healing was
achieved in five out of eight ulcers in the treatment
group compared with one out of eight ulcers in the
control group. The respective results at 1 year follow-
up were five out of eight and 0 out of eight (p 0.026,
Fisher's exact). Furthermore, the median decrease of
the wound areas, at 6 week follow up, in the treatment
group was 100% compared with 52% in the control
group (p 0.027, Mann±Whitney). However, values at
6-month follow-up were 100 and 95% respectively
(Table 2).
Patients in both the treatment and control groups
showed a significant improvement in the depression
score in the HAD Scale (p 0.011 and 0.023 respective-
ly, Wilcoxon) while only the control group had a sig-
nificant reduction in their anxiety score (p 0.042,
Wilcoxon). The SF-36 has detected a significant
improvement in the general health and vitality
domains in the oxygen group (p 0.012 and 0.018
respectively, Wilcoxon) but there was no significant
improvement in the other domains in both groups
and no significant difference between the two groups
overall. In summary, hyperbaric oxygen did not pro-
duce any significant improvements in quality of life
measures greater than those seen in patients in the
control group as measured by the SF-36 and HADS.
During the follow up period, the mean number of
visits for dressing of the study ulcer was 33.75 (62)
per year per patient in the treatment group and 136.5
(126) per year per patient in the control group. The
mean total cost per patient per year for ulcer dressing
visits was £1972 in the treatment group and £7946 in
the control group. Since the cost of the entire hyper-
baric oxygen treatment course per patient was £3000
there was a significant potential cost saving by using
adjunctive hyperbaric oxygen amounting to an aver-
age of £2960 for each patient treated.
Discussion
Wound healing is a physiological response to tissue
damage consisting of a series of events culminating in
repair. However, patients with diabetes exhibit differ-
ent biological responses to those classically described
in the healing process. Multiple factors are involved
in non-healing lower-extremity ulcers in diabetic
patients. Ischaemia, oedema, infection, poor glycae-
mic control, autonomic and sensori-motor neuro-
pathy, and abnormal haemodynamics all impede the
normal healing process.18±22 Wound hypoxia is well
Table 1. Patients' characteristics. OHG (oral hypoglycaemic
therapy), COPD (chronic obstructive pulmonary disease),
GTPI (great toe-brachial pressure index), TcPO2 (transcutaneous
oximetry).
Group Treatment Control p value
Age (years) 72 12.6 70 6.6 NS
Sex (male:female) 2:1 1:2 NS
Diabetes duration (years) 13 9.9 10 6.3 NS
OHG 4/8 3/8 NS
Insulin therapy 4/8 5/8 NS
Retinopathy
Background 7/8 8/8 NS
Proliferative 1/8 0/8 NS
Smokers 1/8 2/8 NS
Neuropathy (Biothesiometer) 47 16.2 55 13.7 NS
SVS classification: Grade 5 8/8 8/8 NS
GTPI 0.47 0.24 0.44 0.3 NS
Foot TcPO2 (mmHg) 46 15 43 19 NS
COPD 1/8 2/8 NS
Cardiac failure 2/8 2/8 NS
Haemoglobin (g/dL) 12.7 1.2 12.5 1.7 NS
Serum albumin (g/L) 37 2.8 38 2.6 NS
Serum urea (mmol/L) 8.5 3.8 7.6 2.9 NS
Body mass index 26 7 29 4 NS
Previous angioplasty 0/8 1/8 NS
Previous bypass surgery 2/8 3/8 NS
Previous amputation
Minor 1/8 2/8 NS
Major 0/8 0/8 NS
Previous ulcers 3/8 4/8 NS
SVS: Society of Vascular Surgery.Results as mean SD.
Table 2. Ulcers description and outcome.
Group Treatment Control p value
Ulcer size (mm2) 106 (12±823) 78 (18±866) NS
Ulcer depth (mm) 2.3 (0.5±4) 1.6 (0.5±4) NS
Wagner Grade I 0 1 NS
Wagner Grade II 8 7 NS
Signs of infection 3/8 2/8 NS
Ulcer duration
(months)
6 (2±18) 9 (3±60) NS
Ulcers healed:
At 6 weeks 5/8 1/8 NS
At 6 months 5/8 2/8 NS
At one year 5/8 0/8 p 0.026
Reduction in ulcer size
At 6 weeks 100%
(34±100)
52%
((ÿ29)±100)
p 0.027
At 6 months 100%
((ÿ206)±100)
95% (0±100) NS
Major amputation 1 1 NS
Minor amputation 1 0 NS
Results as median and (range).
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documented in non-healing wounds, representing the
strongest risk factor in those patients.6,10 Initial studies
have explained the role of oxygen as a metabolite
involved in many basic functions. Studies by Hunt
et al. and Knighton et al. have shown that oxygen
stimulates angiogenesis and enhances fibroblasts
activity and leukocyte function.11,13,14 Siddiqui et al.
have concluded that hyperbaric oxygen also acts as a
stimulus to signal transduction of specific pathways
important for wound healing.23 Abidia et al. have
demonstrated that in diabetic patients with PAD, cuta-
neous microvascular reflexes are normalised under
hyperbaric oxygen conditions.24
Although there are limited data to support most
treatments for diabetic ulcers, six approaches are sup-
ported by clinical trials or well-established principles
of wound healing; off loading, debridement, appro-
priate dressing, management of infection, vascular
reconstruction, and amputation as appropriate.25,26
Adjunctive medical therapies include normalisation
of blood glucose, control of co-morbid conditions,
treatment of oedema, and nutritional therapy. How-
ever, despite advances in medical and surgical care,
14±24% of diabetic patients with lower-extremity
ulcers will require an amputation.3,4,27
The role of oxygen supplement in those patients
with peripheral arterial disease is less clear.15,16 Most
vascular surgeons would accept that improving tissue
perfusion with reconstructive vascular bypass surgery
or angioplasty is an early priority.18 However, on
many occasions such procedures are inappropriate,
impossible or have already failed. Several centres in
the world use hyperbaric oxygen as an adjunctive
treatment for such patients. Nevertheless, few thera-
pies in medicine have encountered such controversy
for so long as has hyperbaric oxygen for chronic
wounds. The lack of sufficient clinical data is partly
because of the difficulty and expenses required in
running clinical trials in this area, the different aeti-
ology of different wounds, and the relatively small
number of patients presenting to centres equipped
with hyperbaric chambers.
Faglia et al. has reported, in a randomised controlled
trial, a significant reduction in major amputation rate
in diabetic patients undergoing hyperbaric oxygen
therapy compared with controls.28 The majority of
patients in this study had advanced ischaemia result-
ing in gangrenous lesions. The control group received
best medical care and the primary endpoint was
lower-extremity amputation. Kalani et al. investigated
the long-term benefit of hyperbaric oxygen therapy in
patients with diabetic foot ulcers. Improved healing
and reduced amputation rate was reported. This
study was also not blinded and the control group
received best medical care.29 Several other authors
have reported favourable results in healing of diabetic
ulcers by using hyperbaric oxygen.30,31 A success rate
of 70±95% was reported, however, these studies were
heavily criticised in their methodology and have been
largely ignored by the medical community. These stu-
dies had several aspects in common: all were non-
blinded; none were randomised and the control
groups were of patients unsuitable for the treatment
or those who refused the treatment; and none had a
placebo control group.16,32
In our study, we targeted diabetic patients
with ischaemic non-healing ulcers in their lower-
extremities in whom vascular intervention was
impossible or considered inappropriate. We have
demonstrated that hyperbaric oxygen treatment at
2.4 ATA for 90 min had significantly reduced the
ulcer size in the lower-extremities of diabetic patients
with PAD compared with those receiving pressurised
air. The response was clinically obvious after 15 treat-
ments and became statistically significant after 30
treatments. Patients in the control group also had a
reduction in their ulcers size albeit at a much slower
rate compared to the treatment group. Eventually the
reduction in ulcer size in the two groups was compar-
able at 6 month follow-up of those patients. Neverthe-
less, despite the reduction in ulcer size in the control
group, all of these ulcers remained unhealed at 1 year
follow up (Table 2). Consequently, the difference in
complete healing between the two groups was statis-
tically significant at 1 year follow-up. Follow-up of
these patients was discontinued after 1 year because the
authors felt that any difference observed between the
two groups beyond one year cannot be confidently
attributed to the hyperbaric oxygen therapy, and is
more likely to be due to natural progression of periph-
eral arterial disease. In agreement with previous stu-
dies in patients with Wagner grade II ulcers, this study
did not show any difference in major or minor ampu-
tation rate between the two groups.
The ulcer healing progress during the study period
shown in Figure 1 indicates that the benefit of hyper-
baric oxygen persisted after discontinuing the treat-
ment. Such an effect, suggests that hyperbaric oxygen
has instigated a process that allowed healing to
continue in an enhanced rate later under normal con-
ditions. In the absence of significant changes in trans-
cutaneous oxygen values of the lower limb at the
end of the study (Table 3), this effect appears to be
mediated through the pharmacological effects of oxy-
gen, i.e., a signal transduction mechanism.
Improvements in the ulcer size in the control group
were slightly better than those reported in the
literature for patients of similar age and extent of
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